Ascentage Pharma presented 17 clinical updates on its key cancer drugs olverembatinib and lisaftoclax at the EHA2026 Congress, showing strong efficacy and safety in treating various blood cancers including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Olverembatinib demonstrated potential as a second-line treatment for resistant CML and showed robust responses in Ph+ ALL patients, while lisaftoclax showed promising results in chronic lymphocytic leukemia (CLL), myeloid neoplasms, and pediatric relapsed/refractory Ph+ ALL. These findings support ongoing global trials and the development of innovative combination therapies to improve patient outcomes worldwide.
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...
Crinetics Pharmaceuticals presented positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist, showing it effectively lowers androgen levels and allows reduction of glucocorticoid doses in adults with classic congenital adrenal ...
Perseus Mining has increased its on-market share buy-back program from AUD100 million to AUD150 million after reaching the initial target. The company has repurchased over 45 million shares since August 2024, reflecting confidence in its strong cash ...
Binance has experienced a pattern of large stablecoin flows, with $83 million in USDT entering daily via Ethereum and $101 million exiting daily via Tron over the past two weeks. This cross-chain activity suggests involvement from whales and institut...
VersaBank has filed an update with the SEC revealing its Digital Meteor initiative, which involves tokenizing bank deposits as Real Bank Tokenized Deposits (RBTDs) on Ethereum, Algorand, and Stellar blockchains. Unlike stablecoins, these RBTDs repres...
